- Niederhuber JE, et al., eds. Cancer of the breast. In: Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed March 4, 2026.
- Breast cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed May 11, 2026.
- Klimberg VS, et al., eds. Bland and Copeland's The Breast: Comprehensive Management of Benign and Malignant Diseases. 6th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed March 4, 2026.
- Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Feb. 2, 2026.
- Ruddy KJ, et al. Approach to the patient following treatment for breast cancer. https://www.uptodate.com/contents/search. Accessed March 4, 2026.
- Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA: A Cancer Journal for Clinicians. 2016; doi:10.3322/caac.21319.
- Eisen A, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. Journal of Clinical Oncology. 2022; doi:10.1200/JCO.21.02647.
- Chirgwin JH, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group I-98 trial of tamoxifen and letrozole, alone and in sequence. Journal of Clinical Oncology. 2016; doi:10.1200/JCO.2015.63.8619.
- DeVita VT Jr, et al., eds. Breast cancer. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Feb 2, 2026.
- Medical review (expert opinion). Mayo Clinic. March 18, 2025.
- Antibody-drug conjugate. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate. Accessed March 23, 2026.
- Come SE. Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse. https://www.uptodate.com/contents/search. Accessed May 11, 2026.
- Pedersen RN, et al. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. Journal of the National Cancer Institute. 2022; doi:10.1093/jnci/djab202.
- Sabel MS, et al. Clinical manifestations and evaluation of locoregional recurrences of breast cancer. https://www.uptodate.com/contents/search. Accessed May 21, 2026.
- Bleiweiss IJ. Pathology of breast cancer. https://www.uptodate.com/contents/search. Accessed May 8, 2026.
- Andre F, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. Journal of Clinical Oncology. 2022; doi:10.1200/JCO.22.00069.
- Yau C, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5,161 patients. The Lancet Oncology. 2022; doi:10.1016/S1470-2045(21)00589-1.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology. 2021; doi:10.1016/S1470-2045(21)00288-6.
- Ko A, et al. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: A systematic review and meta-analysis. Annals of Internal Medicine. 2026; doi:10.7326/ANNALS-25-02237.
- Rock CL, et al. American Cancer Society nutrition and physical activity guide for cancer survivors. CA: A Cancer Journal for Clinicians. 2022; doi:10.3322/caac.21719.
- Panet F, et al. Use of ctDNA in early breast cancer: Analytical validity and clinical potential. NPJ Breast Cancer. 2024; doi:10.1038/s41523-024-00653-3.
- Breast SPOREs. National Cancer Institute. https://dctd.cancer.gov/research/spores/focus-area/breast. Accessed April 17, 2026.
- Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed April 17, 2026.